COMPANY

Brief History, Certification

2022 ~ 2016 2015 ~ 2000

ANYGEN History Since 2000

  • 2022
    • Development of atopic dermatitis treatment (clinical phase 2) / Novacell
    • Acquisition of ISO 45001 certification
    • Selection of Bio-health R&D Project (Government Task) / Ministry of Trade and Industry
  • 2021
    • Contract with Nobelpharma Co., Ltd. For the clinical trial of a long-acting precocious puberty medication in the US.
    • Contract with Cellivery for the Phase 1 clinical trial of production and research service of pharmaceutical ingredients in the US. (About 2.1 billion)
  • 2020
    • Acquisition of KGMP (Osong No.2 GMP facility) / KFDA
  • 2019
    • Selection of Hidden Champion 100 (Materials · Components · Equipment) / Ministry of SMEs and Startups
    • Certificate of “Pre-Hidden Champion” / Mayor of Gwangju Metropolitan City
    • Selection of Promising small business / Jeollanamdo
    • Selection of Promising Export Small and Medium Enterprise / Gwangju&Jeonnam Export Center, MSS
    • Selection of High-tech company / Ministry of Science, ICT and Future Planning
    • Acquisition of patent for manufacturing method of Buserellin
    • Acquisition of patent for manufacturing method of Goserelin
    • MOU and Contract with Aston Science & IntegrityBio for production and research service of pharmaceutical ingredients. (About 1.2 billion)
  • 2018
    • Construction of Osong No.2 GMP facility
    • Completion of clinical trial on AGM-130, Phase 1b.
    • MOU and Contract with HysensBio & integrityBio for production and research service of pharmaceutical ingredients. (About 900 million)
  • 2017
    • Determination of suitability for pharmaceutical manufacturing and quality control standard.
    • Selection of 2017 Korean Small Business Innovation Research Program
      (Government Task)
    • Acquisition of IP CERT
    • Designated as a High Technology Company
    • Designated as a Global IP Star Company
    • Signed contract for process development, production and stability research
      (GPC-3, HSP-70 / CYTLIMIC INC.)
    • Purchase of land and buildings for the expansion of Osong No. 2 plant
  • 2016
    • Listed on KOSDAQ market
    • Acquired export license for Leuprorelin / DCGI(India)
    • Designated as a K-Brain Power 2016~2018
  • 2015
    • Strategic alliance Ziconotide With TherDose Phama Pvt (India)
    • Manufacturing Partnership with TONYMOLY (Cosmetic)
    • Approval of clinical trial on AGM-130, Phase1b.
  • 2014
    • Awarded the Excellence Prize in the 2014 Technology Commercialization Best Practice Division of the Research Special Zone.
    • Strategic alliance With Yuhan Corporation
    • Strategic alliance With LG life Science
    • Leuprorelin DMF (Export Licensing) Registration / China Food and Drug Administration (CFDA)
  • 2013
    • Acquisition of Product License Exenatide / KFDA
    • Acquisition of Product License Ziconotide / KFDA
  • 2012
    • Leuprorelin received DMF / FDA (US Food and Drug Administration)
    • Acquisition of Product License Desmopressin / KFDA
  • 2011
    • Acquisition of Product Notification Leuprorelin / KFDA
    • Acquisition of KGMP/ KFDA
  • 2010
    • Approval of Foreign manufacture / MHLW in JAPAN
    • Completed GMP factory in Jeonnam Nano Bio Center
  • 2006
    • Acquisition of ISO9001,14001 certification
  • 2005
    • Designated as an INNO-biz company
  • 2000
    • Established and recognized as a company-affilated research center
    • Certification of Venture Business / Small and Medium Business Administration
    • Established ANYGEN CO., LTD.,

Certification

Confidence in quality and technology, please check with certification.